Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab +/- Anlotinib with Chemotherapy in Advanced NPC
NCT04736810Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Feb 2021; status: completed.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04736810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04736810.